Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Changes
... 15 Artifacts Summary
.... 15.1 AbsenceOfExposureDefinition
.... 15.2 Adaptation
.... 15.3 BaselineMeasureEvidence
.... 15.4 BaselineMeasureReport
.... 15.5 BaselineVariablesList
.... 15.6 BookCitation
.... 15.7 BookPartCitation
.... 15.8 CertaintyOfEvidence
.... 15.9 Classification
.... 15.10 CohortDefinition
.... 15.11 Comment
.... 15.12 ComparativeBaselineMeasureEvidence
.... 15.13 ComparativeEvidence
.... 15.14 ComparativeEvidenceReport
.... 15.15 ComparativeEvidenceReportExpanded
.... 15.16 ComparativeEvidenceReportSubject
.... 15.17 ComparativeEvidenceSynthesisReport
.... 15.18 ComparativeParticipantFlowEvidence
.... 15.19 ComparatorGroup
.... 15.20 ComparatorOnlyEvidence
.... 15.21 Comparison
.... 15.22 CompositeRating
.... 15.23 ConceptualCohortDefinition
.... 15.24 ConceptualComparatorDefinition
.... 15.25 ConceptualExposureDefinition
.... 15.26 DatabaseCitation
.... 15.27 DatabaseEntryCitation
.... 15.28 DatasetCitation
.... 15.29 DateAsRating
.... 15.30 DichotomousIntendedOutcome
.... 15.31 EndpointAnalysisPlan
.... 15.32 EvidenceAssessment
.... 15.33 EvidenceList
.... 15.34 EvidenceReport
.... 15.35 EvidenceReportPackage
.... 15.36 EvidenceReportSubject
.... 15.37 EvidenceSynthesisEvidence
.... 15.38 ExposureGroup
.... 15.39 GroupAssignment
.... 15.40 GroupR6
.... 15.41 Guideline
.... 15.42 InterventionOnlyEvidence
.... 15.43 JournalArticleCitation
.... 15.44 M11Report
.... 15.45 MetaanalysisEligibilityCriteria
.... 15.46 MetaanalysisOutcomeDefinition
.... 15.47 MetaanalysisStudyGroup
.... 15.48 NetEffectContribution
.... 15.49 NetEffectContributionList
.... 15.50 NetEffectContributions
.... 15.51 NetEffectEstimate
.... 15.52 NonComparativeEvidence
.... 15.53 OutcomeDefinition
.... 15.54 OutcomeImportance
.... 15.55 OutcomeList
.... 15.56 OutcomeMeasureReport
.... 15.57 OutcomeVariablesList
.... 15.58 ParticipantFlowEvidence
.... 15.59 ParticipantFlowEvidenceVariable
.... 15.60 ParticipantFlowReasonEvidenceVariable
.... 15.61 ParticipantFlowReport
.... 15.62 ParticipantFlowVariablesList
.... 15.63 PreprintCitation
.... 15.64 Rating
.... 15.65 Recommendation
.... 15.66 RecommendationAction
.... 15.67 RecommendationEligibilityCriteria
.... 15.68 RecommendationJustification
.... 15.69 RecommendationPlan
.... 15.70 RecommendationRating
.... 15.71 ResearchStudyDataDictionary
.... 15.72 ResearchStudySite
.... 15.73 ResearchStudySupport
.... 15.74 RiskOfBias
.... 15.75 SearchResults
.... 15.76 SearchStrategy
.... 15.77 SingleStudyEvidence
.... 15.78 SoaPlanDefinition
.... 15.79 SoftwareCitation
.... 15.80 StatisticModel
.... 15.81 StudyComponent
.... 15.82 StudyDesign
.... 15.83 StudyEligibilityCriteria
.... 15.84 StudyGroup
.... 15.85 StudyRegistryRecord
.... 15.86 SummaryOfFindings
.... 15.87 SummaryOfNetEffect
.... 15.88 SystematicReview
.... 15.89 SystematicReviewEligibilityCriteria
.... 15.90 SystematicReviewExcludedStudies
.... 15.91 SystematicReviewIncludedStudies
.... 15.92 VariableDefinition
.... 15.93 WebPageCitation
.... 15.94 ArtifactAssessmentCompared
.... 15.95 ArtifactAssessmentDateAsRating
.... 15.96 ArtifactPublicationStatus
.... 15.97 ArtifactRecorder
.... 15.98 CharacteristicTiming
.... 15.99 CiteAs
.... 15.100 EvidenceVariableHandlingDetail
.... 15.101 GuidelineRegistration
.... 15.102 NumberAnalyzed
.... 15.103 RelatesToClassifier
.... 15.104 RelatesToWithQuotation
.... 15.105 RelativeOutcomeImportance
.... 15.106 ResearchStudyExcludedStudy
.... 15.107 ResearchStudyIncludedStudy
.... 15.108 ResearchStudyIsLowInterventionTrial
.... 15.109 ResearchStudyIsRareDisease
.... 15.110 ResearchStudyNumberOfStudiesIdentified
.... 15.111 ResearchStudyNumberOfStudiesIncluded
.... 15.112 ResearchStudySaeReportingMethod
.... 15.113 ResearchStudySearchStrategy
.... 15.114 ResearchStudySponsorConfidentialityStatement
.... 15.115 ResearchStudyStudyAmendment
.... 15.116 ResearchStudySystematicReviewEligibilityCriteria
.... 15.117 StatisticModelExpression
.... 15.118 StatisticModelIncludeIf
.... 15.119 Desirability Codes Value Set
.... 15.120 EBMonFHIR Profile Name Value Set
.... 15.121 Evidence Rating System Classifier Codes Value Set
.... 15.122 Recommendation Justification Classifier Codes Value Set
.... 15.123 Research Study Document Types Value Set
.... 15.124 ResearchStudy Classifier Value Set
.... 15.125 Search Strategy Characteristic Value Set
.... 15.126 Desirability Code System
.... 15.127 EBMonFHIR Profile Name Code System
.... 15.128 Evidence Rating System Classifier Code System
.... 15.129 Research Study Document Types Code System
.... 15.130 Search Strategy Characteristic Code System
.... 15.131 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 15.132 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.133 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 15.134 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 15.135 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 15.136 179899
.... 15.137 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 15.138 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 15.139 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 15.140 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 15.141 19967827 Wonder woman was Argentine and her real name was Evita.
.... 15.142 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 15.143 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 15.144 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 15.145 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 15.146 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 15.147 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 15.148 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 15.149 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 15.150 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 15.151 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 15.152 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 15.153 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 15.154 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 15.155 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 15.156 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 15.157 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 15.158 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 15.159 27979893 6. Glycemic Targets.
.... 15.160 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 15.161 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 15.162 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 15.163 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 15.164 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 15.165 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 15.166 30467172 Finding my inner Wonder Woman.
.... 15.167 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.168 34871555 What Can Wonder Woman Teach Radiologists?
.... 15.169 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 15.170 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 15.171 367832
.... 15.172 367833
.... 15.173 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 15.174 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 15.175 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 15.176 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
.... 15.177 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.178 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.179 Add-on Amlodipine at 6 weeks
.... 15.180 Adults with diabetes mellitus type 2
.... 15.181 Adults with type 2 diabetes and CVD and CKD
.... 15.182 Adults with type 2 diabetes and established CVD (but no CKD)
.... 15.183 Adverse event free and hypertension control
.... 15.184 Adverse event free and hypertension control at 12 weeks
.... 15.185 Adverse Events Report for NCT03421379
.... 15.186 Adverse Events Report for NCT03640312
.... 15.187 Age
.... 15.188 Age with comparator
.... 15.189 Age with intervention
.... 15.190 Aircraft Type
.... 15.191 Aircraft Type with comparator
.... 15.192 Aircraft Type with intervention
.... 15.193 Altitude
.... 15.194 Altitude comparing intervention vs. comparator
.... 15.195 Altitude for enrolled group
.... 15.196 Altitude for screened group
.... 15.197 Altitude with comparator
.... 15.198 Altitude with intervention
.... 15.199 Analyzed Group in PARACHUTE Trial
.... 15.200 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 15.201 Baseline Characteristics Report for NCT03421379
.... 15.202 Baseline Characteristics Report for NCT03640312
.... 15.203 Baseline Characteristics Report for QUARTET Trial
.... 15.204 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.205 Baseline Measures List for PARACHUTE Trial
.... 15.206 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 15.207 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 15.208 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 15.209 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 15.210 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.211 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 15.212 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.213 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.214 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 15.215 Candesartan 8 mg once daily
.... 15.216 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.217 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 15.218 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.219 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.220 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.221 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 15.222 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 15.223 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 15.224 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.225 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.226 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.227 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.228 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.229 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.230 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.231 Citation for EBMonFHIR Implementation Guide
.... 15.232 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.233 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 15.234 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.235 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 15.236 Comparative Evidence Report for QUARTET USA Trial
.... 15.237 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.238 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.239 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.240 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 15.241 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.242 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.243 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.244 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.245 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.246 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 15.247 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 15.248 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 15.249 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 15.250 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 15.251 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 15.252 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 15.253 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 15.254 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 15.255 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 15.256 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 15.257 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 15.258 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 15.259 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 15.260 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 15.261 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.262 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.263 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.264 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.265 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 15.266 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.267 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 15.268 ComparatorDefinition: Standard care
.... 15.269 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.270 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.271 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 15.272 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 15.273 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.274 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.275 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.276 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.277 Composite Rating of FOI 153881 for Project FOI 112280
.... 15.278 Computable_Publishing_LLC
.... 15.279 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 15.280 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.281 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.282 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.283 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.284 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 15.285 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 15.286 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 15.287 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 15.288 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 15.289 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 15.290 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 15.291 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 15.292 ConceptualCohortDefinition: Nonfatal stroke
.... 15.293 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter
.... 15.294 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter with Ranges
.... 15.295 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 15.296 ConceptualCohortDefinition: Severe obesity
.... 15.297 ConceptualCohortDefinition: T1DM or T2DM
.... 15.298 ConceptualCohortDefinition: T1DM-specific criteria
.... 15.299 ConceptualCohortDefinition: T2DM-specific criteria
.... 15.300 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 15.301 ConceptualCohortDefinition_Cardiovascular_event
.... 15.302 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.303 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 15.304 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.305 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 15.306 COVID_19PneumoniaHospitalizedAdult
.... 15.307 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.308 CTIS2024-516402-32-00 Eligibility Criteria
.... 15.309 CTIS2024-516402-32-00 Primary Outcome 1
.... 15.310 CTIS2024-516402-32-00 Secondary Outcome 1
.... 15.311 CTIS2024-516402-32-00 Secondary Outcome 2
.... 15.312 CTIS2024-516402-32-00 Secondary Outcome 3
.... 15.313 CTIS2024-516402-32-00 Secondary Outcome 4
.... 15.314 CTIS2024-516402-32-00 Secondary Outcome 5
.... 15.315 CTIS2024-516402-32-00 Secondary Outcome 6
.... 15.316 CTIS2024-516402-32-00 Secondary Outcome 7
.... 15.317 CTIS2024-516402-32-00 Secondary Outcome 8
.... 15.318 DatabaseCitation: Citation for FEvIR Platform
.... 15.319 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.320 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 15.321 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 15.322 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 15.323 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 15.324 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 15.325 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 15.326 declined randomization in PARACHUTE Study
.... 15.327 deemed unsuitable by investigator in PARACHUTE Trial
.... 15.328 Delany-Moretlwe 2022 clinical trial
.... 15.329 Diabetes treatment medication
.... 15.330 Diastolic blood pressure at 12 weeks
.... 15.331 DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure
.... 15.332 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 15.333 DichotomousIntendedOutcome: New onset depression
.... 15.334 DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke
.... 15.335 DichotomousIntendedOutcome: Remission of diabetes
.... 15.336 DichotomousIntendedOutcome: Treatment with opioids
.... 15.337 DIO: Mortality
.... 15.338 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 15.339 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 15.340 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 15.341 Eligibility criteria for NMA_Diabetes
.... 15.342 Eligibility Criteria for QUARTET USA Trial
.... 15.343 Enrolled Group for QUARTET USA Trial
.... 15.344 Enrolled Group PARACHUTE Trial
.... 15.345 Ethnic Group
.... 15.346 Ethnic Group with comparator
.... 15.347 Ethnic Group with intervention
.... 15.348 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 15.349 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.350 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.351 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 15.352 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 15.353 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.354 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.355 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 15.356 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.357 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.358 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.359 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.360 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.361 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.362 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.363 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 15.364 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.365 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.366 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.367 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 15.368 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.369 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.370 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.371 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.372 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.373 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 15.374 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.375 EvidenceReportSectionCode Value Set
.... 15.376 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.377 EvidenceVariable Handling Extension Value Set
.... 15.378 EvidenceVariable: case_id
.... 15.379 EvidenceVariable: Patient id
.... 15.380 EvidenceVariable: Time of measurement
.... 15.381 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.382 Excluded from PARACHUTE Study
.... 15.383 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 15.384 ExposureVariable: Age (as continuous variable)
.... 15.385 ExposureVariable: Body Mass Index (as continuous variable)
.... 15.386 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 15.387 ExposureVariable: pht013093.v1.p1 RACE
.... 15.388 ExposureVariable: pht013093.v1.p1 SEX
.... 15.389 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 15.390 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 15.391 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 15.392 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 15.393 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 15.394 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 15.395 ExposureVariable: pht013094.v1.p1 Source_Type
.... 15.396 Family History of Parachute Use
.... 15.397 Family History of Parachute Use with comparator
.... 15.398 Family History of Parachute Use with intervention
.... 15.399 Frequent Flier
.... 15.400 Frequent Flier with comparator
.... 15.401 Frequent Flier with intervention
.... 15.402 GLP-1 RA Group in Adults with type 2 diabetes
.... 15.403 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 15.404 Glucagon Hydrochloride Solution (Active Comparator)
.... 15.405 Glucagon Nasal Powder (Experimental)
.... 15.406 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 15.407 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 15.408 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 15.409 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.410 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.411 GroupAssignment: GLP-1 RA vs. Standard care
.... 15.412 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 15.413 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 15.414 GroupAssignment: Non Participants vs. Enrolled Participants
.... 15.415 GroupAssignment: Quadpill vs. Candesartan
.... 15.416 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 15.417 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 15.418 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 15.419 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 15.420 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 15.421 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.422 Health Survey Score Total
.... 15.423 Health Survey Score Total comparing intervention vs. comparator
.... 15.424 Health Survey Score Total with comparator
.... 15.425 Health Survey Score Total with intervention
.... 15.426 Health Survey Score-Mental Health Subscore
.... 15.427 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 15.428 Health Survey Score-Mental Health Subscore with comparator
.... 15.429 Health Survey Score-Mental Health Subscore with intervention
.... 15.430 Health Survey Score-Physical Health Subscore
.... 15.431 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 15.432 Health Survey Score-Physical Health Subscore with comparator
.... 15.433 Health Survey Score-Physical Health Subscore with intervention
.... 15.434 Health-related Quality of Life (NCT03640312)
.... 15.435 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 15.436 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.437 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.438 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 15.439 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.440 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.441 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.442 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.443 Height
.... 15.444 Height with comparator
.... 15.445 Height with intervention
.... 15.446 High Blood Pressure Medication Value Set
.... 15.447 History of Acrophobia
.... 15.448 History of Acrophobia with comparator
.... 15.449 History of Acrophobia with intervention
.... 15.450 History of Broken Bones
.... 15.451 History of Broken Bones with comparator
.... 15.452 History of Broken Bones with intervention
.... 15.453 History of Parachute Use
.... 15.454 History of Parachute Use with comparator
.... 15.455 History of Parachute Use with intervention
.... 15.456 Hypertension Control at 12 weeks
.... 15.457 ICD-10-GM Terminale Codes
.... 15.458 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 15.459 Injury Severity Score 30 days after Impact with comparator
.... 15.460 Injury Severity Score 30 days after Impact with intervention
.... 15.461 Injury Severity Score on Impact comparing intervention vs. comparator
.... 15.462 Injury Severity Score on Impact with comparator
.... 15.463 Injury Severity Score on Impact with intervention
.... 15.464 International vs Domestic Flight
.... 15.465 International vs Domestic Flight with comparator
.... 15.466 International vs Domestic Flight with intervention
.... 15.467 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.468 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 15.469 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.470 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.471 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.472 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.473 Investigator
.... 15.474 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 15.475 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 15.476 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.477 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.478 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.479 Jumping from aircraft with empty backpack
.... 15.480 Jumping from aircraft with parachute
.... 15.481 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.482 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.483 M11 IGBJ Protocol Example Eligibility Criteria
.... 15.484 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 15.485 M11 Report Template Instructions
.... 15.486 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.487 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.488 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.489 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.490 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.491 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.492 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.493 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.494 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.495 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.496 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.497 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.498 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.499 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.500 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.501 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.502 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.503 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.504 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.505 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.506 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.507 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.508 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.509 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.510 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.511 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.512 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.513 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.514 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.515 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.516 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.517 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.518 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.519 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.520 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.521 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.522 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.523 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.524 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.525 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.526 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.527 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.528 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.529 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.530 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.531 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.532 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.533 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.534 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.535 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.536 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.537 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.538 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.539 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.540 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.541 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.542 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.543 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.544 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.545 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.546 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.547 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.548 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.549 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.550 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.551 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.552 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 15.553 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 15.554 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.555 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.556 Mean Change in Serum Creatinine (NCT03640312)
.... 15.557 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 15.558 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.559 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.560 Mean Change in Serum Potassium (NCT03640312)
.... 15.561 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 15.562 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.563 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.564 Mean Change in Serum Sodium (NCT03640312)
.... 15.565 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 15.566 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.567 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.568 Mean Diastolic Blood Pressure (NCT03640312)
.... 15.569 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.570 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.571 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.572 Mean Systolic Blood Pressure (NCT03640312)
.... 15.573 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.574 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.575 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.576 Median Age of Parachute Intervention Group
.... 15.577 Medication Adherence (NCT03640312)
.... 15.578 Medication Adherence at 12 weeks
.... 15.579 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 15.580 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.581 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.582 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.583 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.584 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 15.585 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.586 Mortality at 14 days
.... 15.587 NCT03421379 Eligibility Criteria
.... 15.588 NCT03640312 Eligibility Criteria
.... 15.589 NetEffectContribution for ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.590 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.591 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.592 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.593 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.594 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.595 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 15.596 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 15.597 NetEffectEstimate for SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.598 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 15.599 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 15.600 NHANES LBXGLU Variable Definition Cohort Definition
.... 15.601 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 15.602 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 15.603 NHANES SEQN Respondent Sequence Number
.... 15.604 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 15.605 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 15.606 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 15.607 NT-proBNP Study Data Dictionary
.... 15.608 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 15.609 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 15.610 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.611 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.612 Organ support-free days
.... 15.613 Outcome Importance Rating 100 of All-cause mortality
.... 15.614 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 15.615 Outcome Importance Rating 5 of New onset depression
.... 15.616 Outcome Importance Rating 5 of Remission of diabetes
.... 15.617 Outcome Importance Rating 5 of Treatment with opioids
.... 15.618 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 15.619 Outcome Importance Rating of DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.620 Outcome Importance Rating of DichotomousIntendedOutcome: New onset depression for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.621 Outcome Importance Rating of DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.622 Outcome Importance Rating of DichotomousIntendedOutcome: Remission of diabetes for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.623 Outcome Importance Rating of DichotomousIntendedOutcome: Treatment with opioids for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.624 Outcome Importance Rating of Mortality for Bariatric Surgery Patients
.... 15.625 Outcome Measure List for QUARTET USA Trial
.... 15.626 Outcome Measure Report for QUARTET USA Trial
.... 15.627 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.628 Outcome Measures Report for NCT03421379
.... 15.629 Outcome Measures Report for NCT03640312
.... 15.630 Outcome Variables List for PARACHUTE Trial
.... 15.631 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 15.632 Outcome: Death or Major Traumatic Injury on Impact
.... 15.633 Outcome: Injury Severity Score 30 days after Impact
.... 15.634 Outcome: Injury Severity Score on Impact
.... 15.635 OutcomeDefinition: Injury Severity Score on Impact
.... 15.636 OutcomeDefinition: All-cause mortality
.... 15.637 OutcomeDefinition: All-cause mortality
.... 15.638 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 15.639 OutcomeDefinition: Body weight
.... 15.640 OutcomeDefinition: Body weight
.... 15.641 OutcomeDefinition: Cardiovascular mortality
.... 15.642 OutcomeDefinition: Cardiovascular mortality
.... 15.643 OutcomeDefinition: Diabetes in remission
.... 15.644 OutcomeDefinition: Diabetic ketoacidosis
.... 15.645 OutcomeDefinition: End-stage kidney disease
.... 15.646 OutcomeDefinition: End-stage kidney disease
.... 15.647 OutcomeDefinition: Genital infection
.... 15.648 OutcomeDefinition: HbA1c at 12 months
.... 15.649 OutcomeDefinition: HbA1c at 24 months
.... 15.650 OutcomeDefinition: HbA1c at 36 months
.... 15.651 OutcomeDefinition: HbA1c at 6 months
.... 15.652 OutcomeDefinition: HbA1c at 60 months
.... 15.653 OutcomeDefinition: Health-related quality of life
.... 15.654 OutcomeDefinition: Health-related quality of life
.... 15.655 OutcomeDefinition: Heart failure
.... 15.656 OutcomeDefinition: Heart failure
.... 15.657 OutcomeDefinition: Mortality at 14 days
.... 15.658 OutcomeDefinition: New onset depression
.... 15.659 OutcomeDefinition: Nonfatal myocardial infarction
.... 15.660 OutcomeDefinition: Nonfatal myocardial infarction
.... 15.661 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 15.662 OutcomeDefinition: Nonfatal stroke
.... 15.663 OutcomeDefinition: Nonfatal stroke
.... 15.664 OutcomeDefinition: Serious hyperglycaemia
.... 15.665 OutcomeDefinition: Serious hyperglycaemia
.... 15.666 OutcomeDefinition: Severe gastrointestinal events
.... 15.667 OutcomeDefinition: Severe gastrointestinal events
.... 15.668 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.669 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.670 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 15.671 OutcomeVariable: HbA1c at 12 months
.... 15.672 OutcomeVariable: HbA1c at 24 months
.... 15.673 OutcomeVariable: HbA1c at 36 months
.... 15.674 OutcomeVariable: HbA1c at 6 months
.... 15.675 OutcomeVariable: HbA1c at 60 months
.... 15.676 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.677 OutcomeVariable: New onset depression
.... 15.678 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 15.679 OutcomeVariable: Remission of diabetes
.... 15.680 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.681 OutcomeVariable_Additional_GI_surgical_procedure
.... 15.682 OutcomeVariable_All_cause_mortality
.... 15.683 OutcomeVariable_Treatment_with_opioids
.... 15.684 PARACHUTE Trial baseline characteristics
.... 15.685 PARACHUTE Trial non participants
.... 15.686 PARACHUTE trial participant flow report
.... 15.687 PARACHUTE Trial Participants
.... 15.688 PARACHUTE Trial Participants assigned an empty backpack
.... 15.689 PARACHUTE trial participants assigned parachute
.... 15.690 PARACHUTE Trial Participants available for randomization
.... 15.691 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 15.692 PARACHUTE Trial Participants randomized into groups
.... 15.693 PARACHUTE Trial Participants randomized into groups for screened group
.... 15.694 PARACHUTE Trial Participants randomized into groups with comparator
.... 15.695 PARACHUTE Trial Participants randomized into groups with intervention
.... 15.696 PARACHUTE Trial Participants that completed 30 day follow up
.... 15.697 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 15.698 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 15.699 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 15.700 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 15.701 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 15.702 PARACHUTE Trial Participants that declined randomization
.... 15.703 PARACHUTE Trial Participants with no contact at 30 days
.... 15.704 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 15.705 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 15.706 PARACHUTE Trial Results
.... 15.707 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.708 Parachute vs Empty Backpack in PARACHUTE Trial
.... 15.709 Participant Flow Report for NCT03421379
.... 15.710 Participant Flow Report for NCT03640312
.... 15.711 Participant Flow Report for QUARTET USA Trial
.... 15.712 Participant Flow Variables List for PARACHUTE Trial
.... 15.713 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 15.714 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 15.715 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 15.716 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 15.717 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 15.718 ParticipantFlowMeasure: Exclusion from analysis
.... 15.719 ParticipantFlowMeasure: Inclusion in analysis
.... 15.720 Participants Excluded from PARACHUTE Study
.... 15.721 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 15.722 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 15.723 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.724 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.725 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.726 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 15.727 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.728 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.729 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379
.... 15.730 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 15.731 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 15.732 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.733 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.734 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 15.735 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 15.736 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.737 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.738 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 15.739 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.740 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.741 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.742 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.743 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.744 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.745 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.746 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.747 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.748 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.749 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.750 Placebo
.... 15.751 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.752 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.753 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 15.754 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 15.755 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 15.756 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.757 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.758 Proportion of Patients With Hypertension Control (NCT03640312)
.... 15.759 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 15.760 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 15.761 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 15.762 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 15.763 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 15.764 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 15.765 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.766 Quadpill once daily
.... 15.767 QUARTET USA Trial Control Group
.... 15.768 QUARTET USA Trial Quadpill group
.... 15.769 randomized into groups for PARACHUTE Trial
.... 15.770 Rate of Adverse Events of Special Interest (NCT03640312)
.... 15.771 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 15.772 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.773 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.774 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 15.775 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 15.776 Reasons for exclusion from QUARTET USA Trial
.... 15.777 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 15.778 Recommendation Justification Code System
.... 15.779 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 15.780 Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.781 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 15.782 Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.783 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 15.784 Remdesivir
.... 15.785 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 15.786 ResearchStudy Classifier Code System
.... 15.787 Results Section for NCT03421379
.... 15.788 Results Section for NCT03640312
.... 15.789 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.790 Risk of Bias Assessment of PARACHUTE trial
.... 15.791 Risk Of Bias Type Value Set
.... 15.792 Screened Group PARACHUTE Trial
.... 15.793 Search Strategy for NMA_Diabetes
.... 15.794 SearchResults: PubMed search for Wonder Woman
.... 15.795 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 15.796 SearchStrategy: PubMed search for Wonder Woman
.... 15.797 Sex
.... 15.798 Sex with comparator
.... 15.799 Sex with intervention
.... 15.800 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.801 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 15.802 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 15.803 Spanish or English Value Set
.... 15.804 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.805 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 15.806 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 15.807 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 15.808 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.809 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 15.810 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 15.811 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 15.812 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 15.813 Summary of Findings - QUARTET USA Trial
.... 15.814 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 15.815 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.816 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.817 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.818 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.819 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.820 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.821 Systolic blood pressure at 12 weeks
.... 15.822 Time to integration of results in a recommendation
.... 15.823 VariableDefinition: Comparator
.... 15.824 VariableDefinition: Condition(s)
.... 15.825 VariableDefinition: Date of birth
.... 15.826 VariableDefinition: Date of measurement
.... 15.827 VariableDefinition: Gender
.... 15.828 VariableDefinition: NTproBNP
.... 15.829 VariableDefinition: Unit
.... 15.830 Velocity
.... 15.831 Velocity comparing intervention vs. comparator
.... 15.832 Velocity for enrolled group
.... 15.833 Velocity for non participant group
.... 15.834 Velocity with comparator
.... 15.835 Velocity with intervention
.... 15.836 WebPageCitation: A HEvKA Update Summary
.... 15.837 Weight
.... 15.838 Weight with comparator
.... 15.839 Weight with intervention